文章摘要
尤赛男,丁 磊,孟浩杰,杨宇欣,陈 锐,查小明.聚乙二醇化人重组粒细胞刺激因子防治乳腺癌化疗后骨髓抑制的临床研究[J].南京医科大学学报,2020,(5):693~696
聚乙二醇化人重组粒细胞刺激因子防治乳腺癌化疗后骨髓抑制的临床研究
The clinical study on the prevention and treatment of myelosuppression after chemotherapy for breast cancer with different administration time of pegylated recombinant human granulocyte colony⁃stimulating factor
投稿时间:2019-10-27  
DOI:10.7655/NYDXBNS20200514
中文关键词: 乳腺癌  辅助化疗  骨髓抑制  PEG⁃rhG⁃CSF
英文关键词: breast cancer  adjuvant chemotherapy  myelosuppression  PEG⁃rhG⁃CSF
基金项目:北京希思科临床肿瘤学研究基金会(Y?sy2018?077,Y?JS2019?096);南京医科大学2019大学生创新训练计划项目
作者单位
尤赛男 南京医科大学第一附属医院乳腺病科江苏 南京 210029 
丁 磊 南京医科大学第一附属医院第一临床医学院江苏 南京 210029 
孟浩杰 南京医科大学第一附属医院第一临床医学院江苏 南京 210029 
杨宇欣 南京医科大学第一附属医院第一临床医学院江苏 南京 210029 
陈 锐 南京医科大学第一附属医院乳腺病科江苏 南京 210029 
查小明 南京医科大学第一附属医院乳腺病科江苏 南京 210029 
摘要点击次数: 71
全文下载次数: 51
中文摘要:
      目的:通过研究乳腺癌患者化疗后血常规的动态变化,分析聚乙二醇化人重组粒细胞刺激因子(pegylated recombinant human granulocyte colony?stimulating factor,PEG?rhG?CSF)的药物疗效和作用时间。方法:在65例需接受辅助化疗的乳腺癌患者首次及后续化疗后分别于不同时间段注射PEG?rhG?CSF,并动态监测患者血常规数值。结果:患者首次化疗后外周血白细胞和中性粒细胞计数的最低点出现在第10天左右,经治疗性使用PEG?rhG?CSF后,外周血白细胞和中性粒细胞计数在3~5 d内基本恢复正常水平。同时在后续化疗过程中预防性注射PEG?rhG?CSF可显著降低Ⅲ/Ⅳ骨髓抑制发生率。结论:乳腺癌患者在化疗后第10天骨髓抑制最明显,因而在化疗后第10天检测血常规较为合理。同时预防性使用PEG?rhG?CSF可以降低骨髓抑制的发生率,对于已经出现Ⅲ、Ⅳ度骨髓抑制的患者,仍可以使用,大多数患者在3~5 d内骨髓抑制即可控制。
英文摘要:
      Objective:This study aims to analyze the effect and duration of pegylated recombinant human granulocyte colony?stimulating factor(PEG?rhG?CSF)by studying the dynamic changes of blood routine in breast cancer patients after chemotherapy. Methods:A total of 65 breast cancer patients who needed adjuvant chemotherapy were included. Patients were injected with PEG?rhG?CSF at different time period after the first and subsequent chemotherapy,and the patient’s blood routine results were dynamically monitored. Results:The lowest point in the white blood cell(WBC)count and neutrophil count(NC)occurred around the 10 th day after the first chemotherapy. After the injection of PEG?rhG?CSF,WBC and NC mostly returned to normal levels within 3?5 days. Prophylactic injection of PEG?rhG?CSF in subsequent chemotherapy significantly reduced the incidence of Ⅲ/Ⅳ myelosuppression. Conclusion:Myelosuppression will be the most severe in breast cancer patients on the 10 th day after chemotherapy. Therefore,it is rational to test blood routine on the 10 th day after chemotherapy. Prophylactic injection of PEG?rhG?CSF can reduce the incidence of myelosuppression. PEG?rhG?CSF can still be used in patients with Ⅲ and Ⅳ myelosuppression,and most patients will be cured within 3?5 days.
查看全文   查看/发表评论  下载PDF阅读器